The global preventable cost of cancer drug wastage
In a study on clinical trial data of 22 targeted oral anticancer drugs (University of California San Francisco, San Francisco, CA, USA), researchers showed the median cost associated with discarded pills per patient rounding off to $1750 a year, which is still costly for a payer. “The rate of increa...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2023-09, Vol.24 (9), p.956-956 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 956 |
|---|---|
| container_issue | 9 |
| container_start_page | 956 |
| container_title | The lancet oncology |
| container_volume | 24 |
| creator | Balakrishnan, Vijay Shankar |
| description | In a study on clinical trial data of 22 targeted oral anticancer drugs (University of California San Francisco, San Francisco, CA, USA), researchers showed the median cost associated with discarded pills per patient rounding off to $1750 a year, which is still costly for a payer. “The rate of increase in the cost of anticancer drugs has just skyrocketed, and patients and insurers have a very difficult time paying for them, so wastage in discarded drugs amounts to a huge cost.” According to Bradley, pharmaceutical companies, payers, and patient advocacy groups are equally responsible for addressing drug wastage. |
| doi_str_mv | 10.1016/S1470-2045(23)00381-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2844086785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204523003819</els_id><sourcerecordid>2858623601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-e0cd3020aef6c84b03b9b600dc186fa9d62cc45031d557ba4d52149b63e968223</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRrF8_QQl4qYfo7Gc2J5HiFwge1POy2Z3UlLSpu0nFf-_aqgcvnmYYnndmeAg5pnBOgaqLJyoKyBkIOWb8DIBrmpdbZC-NRS6F1tvrfoOMyH6MMwBaUJC7ZMQLSQsB5R5hz6-YTduusm22DLjCRW-rFjPXxT7r6szZhcOQ-TBMs3cbezvFQ7JT2zbi0Xc9IC8318-Tu_zh8fZ-cvWQOy5onyM4z4GBxVo5LSrgVVkpAO-oVrUtvWLOCQmceimLygovGRUJ4VgqzRg_IOPN3mXo3gaMvZk30WHb2gV2QzRMCwFaFVom9PQPOuuGsEjfJUpqxbgCmii5oVzoYgxYm2Vo5jZ8GArmS6pZSzVfxgzjZi3VlCl38r19qObof1M_FhNwuQEw6Vg1GEx0DSZxvgnoeuO75p8TnxaLg6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2858623601</pqid></control><display><type>article</type><title>The global preventable cost of cancer drug wastage</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Balakrishnan, Vijay Shankar</creator><creatorcontrib>Balakrishnan, Vijay Shankar</creatorcontrib><description>In a study on clinical trial data of 22 targeted oral anticancer drugs (University of California San Francisco, San Francisco, CA, USA), researchers showed the median cost associated with discarded pills per patient rounding off to $1750 a year, which is still costly for a payer. “The rate of increase in the cost of anticancer drugs has just skyrocketed, and patients and insurers have a very difficult time paying for them, so wastage in discarded drugs amounts to a huge cost.” According to Bradley, pharmaceutical companies, payers, and patient advocacy groups are equally responsible for addressing drug wastage.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(23)00381-9</identifier><identifier>PMID: 37517409</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic drugs ; Antitumor agents ; Cancer therapies ; Chemotherapy ; Costs ; Drug dosages ; Insurance policies ; Patients ; Pharmaceutical industry ; Prescription drugs</subject><ispartof>The lancet oncology, 2023-09, Vol.24 (9), p.956-956</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2858623601?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37517409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balakrishnan, Vijay Shankar</creatorcontrib><title>The global preventable cost of cancer drug wastage</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>In a study on clinical trial data of 22 targeted oral anticancer drugs (University of California San Francisco, San Francisco, CA, USA), researchers showed the median cost associated with discarded pills per patient rounding off to $1750 a year, which is still costly for a payer. “The rate of increase in the cost of anticancer drugs has just skyrocketed, and patients and insurers have a very difficult time paying for them, so wastage in discarded drugs amounts to a huge cost.” According to Bradley, pharmaceutical companies, payers, and patient advocacy groups are equally responsible for addressing drug wastage.</description><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Costs</subject><subject>Drug dosages</subject><subject>Insurance policies</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Prescription drugs</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkE1Lw0AQhhdRrF8_QQl4qYfo7Gc2J5HiFwge1POy2Z3UlLSpu0nFf-_aqgcvnmYYnndmeAg5pnBOgaqLJyoKyBkIOWb8DIBrmpdbZC-NRS6F1tvrfoOMyH6MMwBaUJC7ZMQLSQsB5R5hz6-YTduusm22DLjCRW-rFjPXxT7r6szZhcOQ-TBMs3cbezvFQ7JT2zbi0Xc9IC8318-Tu_zh8fZ-cvWQOy5onyM4z4GBxVo5LSrgVVkpAO-oVrUtvWLOCQmceimLygovGRUJ4VgqzRg_IOPN3mXo3gaMvZk30WHb2gV2QzRMCwFaFVom9PQPOuuGsEjfJUpqxbgCmii5oVzoYgxYm2Vo5jZ8GArmS6pZSzVfxgzjZi3VlCl38r19qObof1M_FhNwuQEw6Vg1GEx0DSZxvgnoeuO75p8TnxaLg6k</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Balakrishnan, Vijay Shankar</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20230901</creationdate><title>The global preventable cost of cancer drug wastage</title><author>Balakrishnan, Vijay Shankar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-e0cd3020aef6c84b03b9b600dc186fa9d62cc45031d557ba4d52149b63e968223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Costs</topic><topic>Drug dosages</topic><topic>Insurance policies</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balakrishnan, Vijay Shankar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balakrishnan, Vijay Shankar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The global preventable cost of cancer drug wastage</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>24</volume><issue>9</issue><spage>956</spage><epage>956</epage><pages>956-956</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>In a study on clinical trial data of 22 targeted oral anticancer drugs (University of California San Francisco, San Francisco, CA, USA), researchers showed the median cost associated with discarded pills per patient rounding off to $1750 a year, which is still costly for a payer. “The rate of increase in the cost of anticancer drugs has just skyrocketed, and patients and insurers have a very difficult time paying for them, so wastage in discarded drugs amounts to a huge cost.” According to Bradley, pharmaceutical companies, payers, and patient advocacy groups are equally responsible for addressing drug wastage.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37517409</pmid><doi>10.1016/S1470-2045(23)00381-9</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2023-09, Vol.24 (9), p.956-956 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2844086785 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Antineoplastic drugs Antitumor agents Cancer therapies Chemotherapy Costs Drug dosages Insurance policies Patients Pharmaceutical industry Prescription drugs |
| title | The global preventable cost of cancer drug wastage |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T03%3A41%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20global%20preventable%20cost%20of%20cancer%20drug%20wastage&rft.jtitle=The%20lancet%20oncology&rft.au=Balakrishnan,%20Vijay%20Shankar&rft.date=2023-09-01&rft.volume=24&rft.issue=9&rft.spage=956&rft.epage=956&rft.pages=956-956&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(23)00381-9&rft_dat=%3Cproquest_cross%3E2858623601%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2858623601&rft_id=info:pmid/37517409&rft_els_id=S1470204523003819&rfr_iscdi=true |